Literature DB >> 15517488

Single center experience in primary surgery for medullary thyroid carcinoma.

Jörg Ukkat1, Oliver Gimm, Michael Brauckhoff, Udo Bilkenroth, Henning Dralle.   

Abstract

Medullary thyroid carcinoma (MTC) is a rare disease, and most studies are either based on small numbers or multicenter studies with their inherent difficulties. Since 1995, a total of 440 patients with MTC underwent surgery in our clinic. A primary operation was performed in 188 patients (43% of 440). In 60 patients, the primary operation was performed because of a germline RET mutation ("prophylactic surgery"). Most (84%, 158/188) of the patients had pathologic calcitonin levels. Notably, MTC was found in almost 10% (3/30) of patients with normal calcitonin levels. However, all patients with lymph node metastases (LNMs) had elevated calcitonin levels. Total thyroidectomy (TTx) was performed in all patients. Lymph node dissection (LND) was performed at various extensions: one-compartment LND in 35% (66/188), three-compartment LND in 31% (58/188), and four-compartment LND in 29% (22/188). In general, lymph node dissection increased the likelihood of complications. LNM and distant metastases (DM) correlated with the extent of the primary tumor (pT category). The presence of LNM ranged from 17% (pT1 tumor) to 100% (pT4 tumor), whereas the presence of DM ranged from 0% (pT1 tumor) to 81% (pT4 tumor). Biochemical cure (normal calcitonin levels) was obtained in 72% (137/188) of patients. All 60 patients undergoing prophylactic surgery (tumor stage pT0/pT1) were biochemically cured. In contrast, only 60% (77/128) of the remaining patients were cured. The data suggest that primary surgery should be scheduled as soon as possible to treat patients at a node-negative stage. In the case of normal basal and elevated stimulated calcitonin levels, TTx and cervicocentral LND is recommended. If the basal calcitonin level is elevated, LND should include the cervicolateral compartment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517488     DOI: 10.1007/s00268-004-7608-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma.

Authors:  O Gimm; J Ukkat; H Dralle
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

2.  C-cell hyperplasia preceding medullary thyroid carcinoma.

Authors:  H J Wolfe; K E Melvin; S J Cervi-Skinner; A A Saadi; J F Juliar; C E Jackson; A H Tashjian
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

3.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

4.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

5.  The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study.

Authors:  H Dralle; G F Scheumann; C Proye; F Bacourt; A Frilling; F Limbert; G Gheri; J F Henry; M Berner; B Niederle
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

6.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

7.  Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma.

Authors:  H Dralle; I Damm; G F Scheumann; J Kotzerke; E Kupsch; H Geerlings; R Pichlmayr
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

8.  Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.

Authors:  S A Wells; D D Chi; K Toshima; L P Dehner; C M Coffin; S B Dowton; J L Ivanovich; M K DeBenedetti; W G Dilley; J F Moley
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

9.  Primary hereditary medullary thyroid carcinoma--C-cell morphology and correlation with preoperative calcitonin levels.

Authors:  R Hinze; H J Holzhausen; O Gimm; H Dralle; F W Rath
Journal:  Virchows Arch       Date:  1998-09       Impact factor: 4.064

10.  Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.

Authors:  M E Dottorini; A Assi; M Sironi; G Sangalli; G Spreafico; L Colombo
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

View more
  9 in total

1.  Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.

Authors:  Allen S Ho; Lu Wang; Frank L Palmer; Changhong Yu; Arnbjorn Toset; Snehal Patel; Michael W Kattan; R Michael Tuttle; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2014-11-04       Impact factor: 5.344

2.  Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival.

Authors:  Isabel Peixoto Callejo; José Américo Brito; Carlos Manuel Zagalo; Jorge Rosa Santos
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

3.  Interest of sentinel node biopsy in apparently intrathyroidal medullary thyroid cancer: a pilot study.

Authors:  M Puccini; G Manca; C Ugolini; V Candalise; A Passaretti; J Bernardini; G Boni; P Buccianti
Journal:  J Endocrinol Invest       Date:  2014-06-21       Impact factor: 4.256

Review 4.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

5.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

6.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

7.  Postoperative Nomogram for Predicting Cancer-Specific and Overall Survival among Patients with Medullary Thyroid Cancer.

Authors:  Li Chen; Yizeng Wang; Ke Zhao; Yuyun Wang; Xianghui He
Journal:  Int J Endocrinol       Date:  2020-11-22       Impact factor: 3.257

Review 8.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

9.  A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.

Authors:  Talia L Fuchs; Anthony J Nassour; Anthony Glover; Mark S Sywak; Stan B Sidhu; Leigh W Delbridge; Roderick J Clifton-Bligh; Matti L Gild; Venessa Tsang; Bruce G Robinson; Adele Clarkson; Amy Sheen; Loretta Sioson; Angela Chou; Anthony J Gill
Journal:  Am J Surg Pathol       Date:  2020-10       Impact factor: 6.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.